{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:38Z","timestamp":1791618998852,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP16K09530"],"award-info":[{"award-number":["JP16K09530"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of surfactant proteins within the alveolar spaces. Autoimmune PAP (APAP) caused by elevated levels of GM-CSF autoantibodies (GM-Ab) is very rarely associated with systemic autoimmune disease. Here we report a case of APAP manifested during immunosuppressive treatment for polymyositis with interstitial lung disease.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 52-year-old woman treated at our hospital because of polymyositis with interstitial pneumonia had maintained remission by immunosuppressive treatment for 15 years. She had progressive dyspnea subsequently over several months with her chest CT showing ground-glass opacities (GGO) in bilateral geographic distribution. Her bronchoalveolar lavage fluid with cloudy appearance revealed medium-sized foamy macrophages and PAS-positive amorphous eosinophilic materials by cytological examination. We diagnosed her as APAP due to an increased serum GM-CSF autoantibody level. Attenuating immunosuppression failed to lead GGO improvement, but whole lung lavage (WLL) was effective in her condition.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>PAP should be considered as one of the differential diseases when the newly interstitial shadow was observed during immunosuppressive treatment. WLL should be regarded as the treatment option for APAP concurred in connective tissue disease (CTD).<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-020-1110-5","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T09:04:11Z","timestamp":1586163851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Autoimmune pulmonary alveolar proteinosis developed during immunosuppressive treatment in polymyositis with interstitial lung disease: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-9038","authenticated-orcid":false,"given":"S.","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tsumiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"1110_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1164\/rccm.2109105","volume":"166","author":"JF Seymour","year":"2002","unstructured":"Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215\u201335.","journal-title":"Am J Respir Crit Care Med"},{"key":"1110_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-019-0066-3","volume":"5","author":"BC Trapnell","year":"2019","unstructured":"Trapnell BC, Nakata K, Bonella F, Campo I, Griese M, Hamilton J, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019;5:16.","journal-title":"Nat Rev Dis Primers"},{"key":"1110_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1183\/09031936.00092910","volume":"37","author":"H Ishii","year":"2011","unstructured":"Ishii H, Tazawa R, Kaneko C, Saraya T, Inoue Y, Hamano E, et al. Clinical features of secondary pulmonary alveolar proteinosis: premortem cases in Japan. Eur Respir J. 2011;37:465\u20138.","journal-title":"Eur Respir J"},{"key":"1110_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1164\/rccm.200708-1271OC","volume":"177","author":"Y Inoue","year":"2008","unstructured":"Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752\u201362.","journal-title":"Am J Respir Crit Care Med"},{"key":"1110_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1177\/0961203313498798","volume":"22","author":"J Nagasawa","year":"2013","unstructured":"Nagasawa J, Kurasawa K, Maezawa R, Owada T, Hanaoka R, Fukuda T. Systemic lupus erythematosus complicating autoimmune pulmonary alveolar proteinosis that was worsened by immunosuppressive therapy. Lupus. 2013;22:1060\u20133.","journal-title":"Lupus."},{"key":"1110_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1620\/tjem.243.77","volume":"243","author":"M Yamasue","year":"2017","unstructured":"Yamasue M, Nureki SI, Usagawa Y, Ono T, Matsumoto H, Kan T, et al. Elevated serum anti-GM-CSF antibodies before the onset of autoimmune pulmonary alveolar Proteinosis in a patient with Sarcoidosis and systemic sclerosis. Tohoku J Exp Med. 2017;243:77\u201383.","journal-title":"Tohoku J Exp Med"},{"key":"1110_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3109\/14397595.2016.1153443","volume":"28","author":"Y Imura","year":"2018","unstructured":"Imura Y, Yukawa N, Handa T, Nakashima R, Murakami K, Yoshifuji H, et al. Two cases of autoimmune and secondary pulmonary alveolar proteinosis during imunosuppressive therapy in dermatomyositis with interstitial lung disease. Mod Rheumatol. 2018;28:724\u20139.","journal-title":"Mod Rheumatol"},{"key":"1110_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.alit.2017.02.002","volume":"66","author":"S Ito","year":"2017","unstructured":"Ito S, Wakahara K, Kojima T, Takahashi N, Nishiwaki K, Yamaguchi E, et al. Two cases of autoimmune pulmonary alveolar proteinosis with rheumatoid arthritis. Allergol Int. 2017;66:507\u20139.","journal-title":"Allergol Int"},{"key":"1110_CR9","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.2169\/internalmedicine.0555-17","volume":"57","author":"N Sakamoto","year":"2018","unstructured":"Sakamoto N, Nakashima S, Ishimoto H, Kakugawa T, Hara A, Yura H, et al. Pulmonary alveolar Proteinosis with ulcerative colitis. Intern Med. 2018;57:2705\u20138.","journal-title":"Intern Med"},{"key":"1110_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jim.2013.11.011","volume":"402","author":"K Uchida","year":"2014","unstructured":"Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods. 2014;402:57\u201370.","journal-title":"J Immunol Methods"},{"key":"1110_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1164\/ajrccm.162.2.9910032","volume":"162","author":"T Kitamura","year":"2000","unstructured":"Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;162:658\u201362.","journal-title":"Am J Respir Crit Care Med"},{"key":"1110_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12890-015-0085-0","volume":"15","author":"K Akasaka","year":"2015","unstructured":"Akasaka K, Tanaka T, Kitamura N, Ohkouchi S, Tazawa R, Takeda T, et al. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulm Med. 2015;15:88.","journal-title":"BMC Pulm Med"},{"key":"1110_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/0002-9343(87)90166-5","volume":"82","author":"DO Wilson","year":"1987","unstructured":"Wilson DO, Rogers RM. Prolonged spontaneous remission in a patient with untreated pulmonary alveolar proteinosis. Am J Med. 1987;82:1014\u20136.","journal-title":"Am J Med"},{"key":"1110_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM197501302920504","volume":"292","author":"JJ Rinehart","year":"1975","unstructured":"Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF. Effects of corticosteroid therapy on human monocyte function. N Engl J Med. 1975;292:236\u201341.","journal-title":"N Engl J Med"},{"key":"1110_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/pulp.1994.1004","volume":"7","author":"M Linden","year":"1994","unstructured":"Linden M, Brattsand R. Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6. Pulm Pharmacol. 1994;7:43\u20137.","journal-title":"Pulm Pharmacol"},{"key":"1110_CR16","doi-asserted-by":"publisher","unstructured":"Kitamura N, Ohkouchi S, Tazawa R, Ishii H, Takada T, Sakagami T, et al. Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution. ERJ Open Res. 2019. https:\/\/doi.org\/10.1183\/23120541.","DOI":"10.1183\/23120541"},{"key":"1110_CR17","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, Chalk C, Do T, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71:1943\u201354.","journal-title":"Arthritis Rheumatol"},{"key":"1110_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213179","volume":"14","author":"K Anderson","year":"2019","unstructured":"Anderson K, Carey B, Martin A, Roark C, Chalk C, et al. Pulmonary alveolar proteinosis: an autoimmune disease lacking an HLA association. PLoS One. 2019;14:e0213179. https:\/\/doi.org\/10.1371\/journal.pone.0213179.","journal-title":"PLoS One"},{"key":"1110_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1183\/09031936.00197710","volume":"38","author":"MS Kavuru","year":"2011","unstructured":"Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011;38:1361\u20137.","journal-title":"Eur Respir J"},{"key":"1110_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00408-014-9678-2","volume":"193","author":"B Garber","year":"2015","unstructured":"Garber B, Albores J, Wang T, Neville TH. A plasmapheresis protocol for refractory pulmonary alveolar proteinosis. Lung. 2015;193:209\u201311.","journal-title":"Lung."},{"key":"1110_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1816216","volume":"381","author":"R Tazawa","year":"2019","unstructured":"Tazawa R, Ueda T, Abe M, Tasumi K, Eda R, Kondoh S, et al. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med. 2019;381:923\u201332.","journal-title":"N Engl J Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-020-1110-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T23:05:42Z","timestamp":1617663942000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-1110-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1110"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-1110-5","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written, informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}